Opioid abuse and hospitalization rates in patients with schizophrenia

References

• Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand 2007;115:304–9.
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006;188:237–42.
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511–18.
   Google Scholar
• Swofford CD, Scheller-Gilkey G, Miller AH, Woolwine B, Mance R. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse 2000;26:343–53.
   PubMed Web of Science ®Google Scholar
• Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216–22.
   PubMed Web of Science ®Google Scholar
• Schmidt LM, Hesse M, Lykke J. The impact of substance use disorders on the course of schizophrenia – a 15-year follow-up study: dual diagnosis over 15 years. Schizophr Res 2011;130:228–33.
   PubMed Web of Science ®Google Scholar
• Duke PJ, Pantelis C, McPhillips MA, Barnes TRE. Comorbid non-alcohol substance misuse among people with schizophrenia. Br J Psychiatry 2001;179:509–13.
   PubMed Web of Science ®Google Scholar
• Mueser KT, Yarnold PR, Rosenberg SD, Swett Jr C, Miles KM, Hill D. Substance use disorder in hospitalized severely mentally ill psychiatric patients: Prevalence, correlates and subgroups. Schizophr Bull 2000;26:179–92.
   PubMed Web of Science ®Google Scholar
• Helseth V, Lykke-Enger T, Johnsen J, Waal H. Substance use disorders among psychotic patients admitted to inpatient psychiatric care. Nord J Psychiatry 2009;63:72–7.
   PubMed Web of Science ®Google Scholar
• Cantor-Graae E, Nordström LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001;48:69–82.
   PubMed Web of Science ®Google Scholar
• Ringen PA, Melle I, Birkenaes AB, Engh JA, Faerden A, Jónsdóttir H, et al. Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study. Acta Psychiatr Scand 2008;117:133–8.
   PubMed Web of Science ®Google Scholar
• Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar 1 disorders in a general population. Arch Gen Psychiatry 2007;64:19–28.
   PubMed Web of Science ®Google Scholar
• Tanhua H, Virtanen A, Knuuti U, Leppo A, Kotovirta E. Drug situation in Finland 2011. 2011 National report to the EMCDDA by the Reitox National Focal Point, THL. Available from http://www.thl.fi/thl-client/pdfs//20bb4ac2-9418-4ec4-a8ec-2f6bb36befb9
   Google Scholar
• European Monitoring Center for Drugs and Drug Addiction. Drug profiles. Available from http://www.emcdda.europa.eu/publications/drug-profiles
   Google Scholar
• Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006;32:637–43.
   PubMed Web of Science ®Google Scholar
• Mesholam-Gately RI, Gibson LE, Seldman LI, Green AI. Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. Schizophr Res 2014;155:45–51.
   PubMed Web of Science ®Google Scholar
• De Hert M, Wampers M, Jendricko T, Franic T, Vidovic D, De Vriendt N, et al. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. Schizophr Res 2011;126:270–6.
   PubMed Web of Science ®Google Scholar
• Myles N, Newall H, Nielssen O, Large M. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Curr Pharm Des 2012;18:5055–69.
   PubMed Web of Science ®Google Scholar
• Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical sample of patients with schizophrenia: a meta-analysis. Schizophr Bull 2010;36:1115–30.
   PubMed Web of Science ®Google Scholar
• Niemi-Pynttäri JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry 2013;74:94–9.
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004;184:110–17.
   PubMed Web of Science ®Google Scholar
• Proal AC, Fleming J, Galvez-Buccollini JA, DeLisi LE. A controlled family study of cannabis users with and without psychosis. Schizophr Res 2014;152:238–8.
   Web of Science ®Google Scholar
• van Dijk D, Koeter MWJ, Hijman R, Kahn RS, van den Brink W. Effect of cannabis use on the course of schizophrenia in male patients: A prospective cohort study. Schizophr Res 2012;137:50–7.
   PubMed Web of Science ®Google Scholar
• Caspari D. Cannabis and schizophrenia: Results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 1999;249:45–9.
   PubMed Web of Science ®Google Scholar
• Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2015;2:233–38.
   PubMed Web of Science ®Google Scholar
• Freeman TP, Morgan CJ, Hindocha C, Schafer G, Das RK, Curran HV. Just say “know”: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction 2014;109:1686–94.
   PubMed Web of Science ®Google Scholar
• Dalmau A, Bergman B, Brismar B. Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness? Eur Psychiatry 1999;14:366–71.
   PubMed Web of Science ®Google Scholar
• Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry 2004;185:196–204.
   PubMed Web of Science ®Google Scholar
• Volkow N. Substance use disorders in schizophrenia – clinical implications of comorbidity. Schizophr Bull 2009;35:469–72.
   PubMed Web of Science ®Google Scholar
• Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner R, Burns BJ. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am J Psychiatry 1998;155:226–31.
   PubMed Web of Science ®Google Scholar
• Mueser KT, Rosenberg SD, Drake RE, Miles KM, Wolford G, Vidaver R, Carrieri K. Conduct disorder, antisocial personality disorder and substance use disorders in schizophrenia and major affective disorders. J Stud Alcohol Drugs 1999;60:278–84.
   PubMed Web of Science ®Google Scholar
• Bizzarri JV1, Rucci P, Sbrana A, Miniati M, Raimondi F, Ravani L, et al. Substance use in severe mental illness: self-medication and vulnerability factors. Psychiatry Res 2009;165:88–95.
   PubMed Web of Science ®Google Scholar